NASDAQ:BLTE Belite Bio (BLTE) Stock Price, News & Analysis $169.44 -3.56 (-2.06%) Closing price 04:00 PM EasternExtended Trading$169.53 +0.09 (+0.05%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Belite Bio Stock (NASDAQ:BLTE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Belite Bio alerts:Sign Up Key Stats Today's Range$168.40▼$173.0150-Day Range$146.68▼$193.6152-Week Range$64.80▼$200.00Volume151,849 shsAverage Volume201,046 shsMarket Capitalization$6.82 billionP/E RatioN/ADividend YieldN/APrice Target$218.73Consensus RatingModerate Buy Company Overview Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for serious retinal diseases. The company’s research centers on therapies designed to address the underlying biological processes that contribute to vision loss, including the accumulation of toxic vitamin A–derived compounds in the retina. Belite Bio’s lead product candidate is tinlarebant, also known as LBS-008. Tinlarebant is an orally administered retinol-binding protein 4 antagonist intended to reduce the delivery of vitamin A to the retina and limit the formation of toxic bisretinoids. The company is evaluating tinlarebant in Stargardt disease, an inherited retinal disorder, and geographic atrophy associated with dry age-related macular degeneration. Founded in 2018 and headquartered in San Diego, California, Belite Bio conducts clinical development activities in multiple geographic markets. The company’s pipeline remains focused on ophthalmic diseases with significant unmet medical needs, and its product candidates are investigational and have not been established as safe or effective for commercial use.AI Generated. May Contain Errors. Read More Belite Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks71st Percentile Overall ScoreBLTE MarketRank™: Belite Bio scored higher than 71% of companies evaluated by MarketBeat, and ranked 218th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingBelite Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.64, and is based on no strong buy ratings, 8 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialBelite Bio has a consensus price target of $218.73, representing about 29.1% upside from its current price of $169.44.Amount of Analyst CoverageBelite Bio has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Belite Bio's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Belite Bio are expected to grow in the coming year, from ($3.08) to $0.91 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Belite Bio is -62.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Belite Bio is -62.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBelite Bio has a P/B Ratio of 8.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Belite Bio's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.01% of the float of Belite Bio has been sold short.Short Interest Ratio / Days to CoverBelite Bio has a short interest ratio ("days to cover") of 7.42.Change versus previous monthShort interest in Belite Bio has recently decreased by 5.96%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBelite Bio does not currently pay a dividend.Dividend GrowthBelite Bio does not have a long track record of dividend growth. News and Social Media2.1 / 5News Sentiment0.34 News SentimentBelite Bio has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.80 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Belite Bio this week, compared to 5 articles on an average week.Search InterestOnly 3 people have searched for BLTE on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Company Ownership1.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Belite Bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $34,876,574.00 in company stock.Percentage Held by Insiders13.29% of the stock of Belite Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions0.53% of the stock of Belite Bio is held by institutions.Read more about Belite Bio's insider trading history. Receive BLTE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Belite Bio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BLTE Stock News HeadlinesBelite Bio, Inc (BLTE) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 14 at 6:29 PM | seekingalpha.comHao-Yuan Chuang Sells 49,433 Shares of Belite Bio (NASDAQ:BLTE) StockSeptember 11, 2026 | americanbankingnews.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.September 15 at 1:00 AM | Stansberry Research (Ad)Yu-Hsin Lin Sells 26,000 Shares of Belite Bio (NASDAQ:BLTE) StockSeptember 11, 2026 | americanbankingnews.comInsider Selling: Belite Bio (NASDAQ:BLTE) CFO Sells $3,528,096.04 in StockSeptember 10, 2026 | insidertrades.comBelite Bio On Track For A Potential Blockbuster Launch In 2027September 9, 2026 | seekingalpha.comBelite Bio Submits Japan Application for Stargardt Disease DrugSeptember 8, 2026 | finance.yahoo.comInsider Selling: Belite Bio (NASDAQ:BLTE) CEO Sells $65,827.75 in StockAugust 15, 2026 | insidertrades.comSee More Headlines BLTE Stock Analysis - Frequently Asked Questions How have BLTE shares performed this year? Belite Bio's stock was trading at $159.96 at the beginning of 2026. Since then, BLTE shares have increased by 5.9% and is now trading at $169.44. How were Belite Bio's earnings last quarter? Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) announced its earnings results on Tuesday, June, 30th. The company reported ($0.54) earnings per share for the quarter. When did Belite Bio IPO? Belite Bio (BLTE) raised $36 million in an initial public offering (IPO) on Friday, April 22nd 2022. The company issued 6,000,000 shares at a price of $5.50-$6.50 per share. Who are Belite Bio's major shareholders? Belite Bio's top institutional shareholders include Squarepoint Ops LLC (0.02%) and Engineers Gate Manager LP (0.01%). Insiders that own company stock include Yu-Hsin Lin, Hao-Yuan Chuang, Hendrik Peter Scholl, Wan-Shan Chen and Nathan L Mata. View institutional ownership trends. How do I buy shares of Belite Bio? Shares of BLTE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Belite Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Belite Bio investors own include Paycom Software (PAYC), Centrus Energy (LEU), Planet Labs PBC (PL), uniQure (QURE), Vale (VALE). Company Calendar Last Earnings6/30/2026Today9/15/2026H.C. Wainwright 28th Annual Global Investment Conference9/15/2026Next Earnings (Estimated)11/09/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 BLTE's financial health is in the Green zone, according to TradeSmith. BLTE has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:BLTE CIK1889109 Webbelitebio.com Phone858-246-6240FaxN/AEmployees41Year Founded2018Price Target and Rating Average Price Target for Belite Bio$218.73 High Price Target$303.00 Low Price Target$132.00 Potential Upside/Downside+29.1%Consensus RatingModerate Buy Rating Score (0-4)2.64 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($2.73) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$77.61 million Net MarginsN/A Pretax MarginN/A Return on Equity-11.84% Return on Assets-11.62% Debt Debt-to-Equity RatioN/A Current Ratio33.56 Quick Ratio33.56 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$20.54 per share Price / Book8.25Miscellaneous Outstanding Shares40,270,000Free Float34,920,000Market Cap$6.82 billion OptionableNot Optionable Beta-1.23 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:BLTE) was last updated on 9/15/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredYour withdrawal order could cost you in taxesIf you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Belite Bio, Inc. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Belite Bio With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
